Intake of chayote extract (sechium edule) for treatment of metabolic syndrome in older adults

Effect of intake of sechium edule (chayote) extract on oxidative stress, chronic inflammation and DNA damage in older adults with metabolic syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN43215432

Enrollment

120

Registered

2018-06-21

Start date

2018-06-21

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic syndrome Nutritional, Metabolic, Endocrine Metabolic syndrome

Interventions

Participants are randomly allocated to one of three groups. Those in the first group are asked to take two capsules that contain 500 mg of Sechium edule extract every day for 12 months. Those in the s

and the third group go without treatment. At the beginning of the study and after three, six and 12 months, the blood pressure (systolic and diastolic) and anthropometric measures are taken (height, w

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age from 60 to 74 years old 2. Diagnosed with metabolic syndrome 3. Have taken antioxidant and / or anti-inflammatory supplements in the last 6 months 4. Signature of informed consent

Exclusion criteria

Exclusion criteria: 1. Without kidney damage 2. Without liver damage 3. Without cancer

Design outcomes

Primary

Measure	Time frame
1. Markers of oxidative stress in blood: isopeotans measured by ELISA, antioxidant enzymes superoxide dismutase (SOD) and glutathione peroxidase (GPx), and total antioxidant activity evaluated through the spectrophotometry technique at baseline at 3, 6 and 12 months 2. Markers of chronic inflammation in blood are measured by flow cytometry: TNF-a, IL-1ß, IL-6, IL-8, IL-1, IL-12p70, at baseline, 3, 6 and 12 months 3. Oxidative damage to DNA is measured through the comet assay technique at the beginning, 3, 6 and 12 months	—

Measure

Time frame

1. Markers of oxidative stress in blood: isopeotans measured by ELISA, antioxidant enzymes superoxide dismutase (SOD) and glutathione peroxidase (GPx), and total antioxidant activity evaluated through the spectrophotometry technique at baseline at 3, 6 and 12 months 2. Markers of chronic inflammation in blood are measured by flow cytometry: TNF-a, IL-1ß, IL-6, IL-8, IL-1, IL-12p70, at baseline, 3, 6 and 12 months 3. Oxidative damage to DNA is measured through the comet assay technique at the beginning, 3, 6 and 12 months

—

Secondary

Measure	Time frame
1. Blood glucose concentration, triglycerides, cholesterol and HDL are measured by spectrometry, and glycosylated hemoglobin is measured by turbidimetry, at baseline 3, 6 and 12 months 2. Systolic and diastolic blood pressure is measured with a mercury sphygmomanometer, at baseline, 3, 6 and 12 months 3. Weight, body mass index, waist and hip circumference are measured at baseline, 3, 6 and 12 months	—

Measure

Time frame

1. Blood glucose concentration, triglycerides, cholesterol and HDL are measured by spectrometry, and glycosylated hemoglobin is measured by turbidimetry, at baseline 3, 6 and 12 months 2. Systolic and diastolic blood pressure is measured with a mercury sphygmomanometer, at baseline, 3, 6 and 12 months 3. Weight, body mass index, waist and hip circumference are measured at baseline, 3, 6 and 12 months

—

Countries

Mexico

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026